- Home
- PIII vs LSTA Comparison
PIII vs LSTA Comparison
Compare PIII & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | LSTA |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 20.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | LSTA |
|---|---|---|
| Price | $3.73 | $2.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $16.25 | ★ $23.50 |
| AVG Volume (30 Days) | 11.3K | ★ 23.5K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | $1,070,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.50 | $1.81 |
| 52 Week High | $14.50 | $4.20 |
Technical Indicators
Market Signals| Indicator | PIII | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 20.91 | 47.86 |
| Support Level | $3.50 | $2.00 |
| Resistance Level | $5.20 | $2.17 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 5.70 | 52.00 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.